alanyltyrosine has been researched along with Cancer of Prostate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buncic, G; Cullinane, C; Donnelly, PS; Haskali, MB; Hicks, RJ; McInnes, LE; Roselt, PD; Van Zuylekom, JK; Waldeck, K; Zia, NA | 1 |
| Del Pozzo, L; Donnelly, PS; Gourni, E; Kheirallah, E; Maecke, HR; Meyer, PT; Paterson, BM; Reubi, JC; Smerling, C; Waser, B | 1 |
2 other study(ies) available for alanyltyrosine and Cancer of Prostate
| Article | Year |
|---|---|
A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper-64 with High Tumor Uptake and Retention.
Topics: Animals; Antigens, Surface; Binding Sites; Cell Line, Tumor; Copper Radioisotopes; Dipeptides; Glutamate Carboxypeptidase II; Glutamates; Humans; Lysine; Male; Mice; Prostatic Neoplasms; Protein Binding; Radiopharmaceuticals; Theranostic Nanomedicine; Tissue Distribution; Urea | 2019 |
Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate Cancer.
Topics: Animals; Copper Radioisotopes; Dipeptides; Female; Heterocyclic Compounds; Humans; Male; Mice; Mice, Nude; Peptide Fragments; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Receptors, Bombesin; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |